If you have Crohn's disease and are considering Mounjaro for weight management, it is reasonable to have questions about whether it is suitable for you. Crohn's disease is not specifically listed as a contraindication to Mounjaro, but the medicine has not been studied in people with severe gastrointestinal disease, including severe gastroparesis, and it can cause gastrointestinal side effects.
There is also a limited amount of research specifically looking at Mounjaro and inflammatory bowel disease. People with IBD were excluded from the main clinical trials used to establish tirzepatide's safety and effectiveness, so more recent evidence mainly comes from observational studies.
This guide explains what the UK prescribing information says, what current research tells us, what remains uncertain, and why it is important to consider your Crohn's disease activity and medical history before starting treatment.
Key things to know
- Mounjaro's prescribing information advises caution in people with severe gastrointestinal disease, including severe gastroparesis. Crohn's disease itself is not listed as a contraindication.
- People with IBD were excluded from the main clinical trials of tirzepatide, so evidence in Crohn's disease comes mainly from observational research.
- Current observational research has not shown a clear increase in IBD flare rates with GLP 1 medicines, but this evidence is not the same as a large randomised clinical trial.
- Crohn's disease can cause strictures and bowel narrowing. If you have a history of bowel obstruction or significant narrowing, this is important information for your prescriber because Mounjaro can affect gastrointestinal movement.
What the Prescribing Information Actually Says
The UK prescribing information states that tirzepatide has not been studied in people with severe gastrointestinal disease, including severe gastroparesis, and advises caution in these patients. Crohn's disease is not specifically listed as a contraindication.
This does not mean that Mounjaro is automatically unsuitable if you have Crohn's disease. It means your individual situation matters. Your prescriber may need to consider your current disease activity, previous complications, bowel symptoms, other medicines and overall health before deciding whether treatment is appropriate.
Mounjaro can also cause gastrointestinal side effects such as nausea, vomiting and diarrhoea. These symptoms can be particularly important to monitor if you already have digestive symptoms because of Crohn's disease.
The Evidence Gap Worth Being Honest About
People with inflammatory bowel disease, including Crohn's disease, were excluded from the pivotal clinical trials of GLP 1 medicines used for weight management. This means the evidence available for people with IBD is not as strong as the evidence available for the general population.
That does not mean the medicines have been shown to be unsafe in Crohn's disease. More recent observational research is relatively reassuring. A 2025 systematic review and meta analysis included 11 observational studies involving 16,242 people with IBD who were treated with GLP 1 receptor agonists. The studies included people with both Crohn's disease and ulcerative colitis, and the analysis did not find an increased rate of IBD exacerbations.
A separate systematic review published in 2025 and appearing in the 2026 issue of Alimentary Pharmacology & Therapeutics included 14 studies. Most were retrospective studies, and the review found that GLP 1 medicines were not associated with increased IBD exacerbations across the available datasets. Gastrointestinal side effects were the main type of adverse event reported.
These findings are encouraging, but they should not be treated as proof that Mounjaro is safe for every person with Crohn's disease. Observational studies can have limitations, and dedicated clinical trials in people with IBD are still needed.
Why Crohn's Specifically Needs Its Own Consideration
Crohn's disease can affect different parts of the gastrointestinal tract and can cause inflammation that extends through the bowel wall. In some people, this can lead to strictures, which are narrowed areas of the intestine.
This matters because Mounjaro can slow gastric emptying and can cause gastrointestinal symptoms such as constipation, nausea and vomiting.
There is not enough evidence to say that Mounjaro causes bowel obstruction in people with Crohn's disease. However, if you already have a known stricture, previous bowel obstruction or symptoms that suggest a blockage, your prescriber should know about this before treatment starts.
Symptoms such as severe or worsening abdominal pain, repeated vomiting, marked abdominal swelling or an inability to pass stool or gas need prompt medical assessment. Do not assume that these symptoms are simply a side effect of Mounjaro.
Telling a Side Effect From a Flare
This is one of the most difficult parts of using Mounjaro when you have Crohn's disease.
Mounjaro can cause gastrointestinal symptoms such as nausea, vomiting and diarrhoea. Crohn's disease can cause some of the same symptoms, particularly diarrhoea and abdominal pain. This can make it difficult to tell whether a new symptom is related to the medicine or your underlying condition.
Faecal calprotectin can be useful here. It is a stool test that can help assess inflammation in the bowel and is commonly used when monitoring IBD. However, it is not a perfect test and cannot, by itself, prove whether a symptom is caused by Mounjaro or a Crohn's flare.
Your IBD team may also consider your symptoms, blood tests, previous results and other investigations when assessing possible disease activity. If you are starting Mounjaro, it may be helpful to ask your IBD team what symptoms should prompt you to contact them and whether any monitoring is appropriate for you.
Rectal bleeding should also be assessed rather than automatically being blamed on Mounjaro. Bleeding can have several causes, including active bowel inflammation, haemorrhoids or other gastrointestinal problems.
A Red Flag Worth Knowing
Unintentional weight loss can be a sign of active Crohn's disease, reduced food intake or other health problems. It is therefore important to understand why you are losing weight before starting an appetite reducing treatment.
If you have been losing weight without trying, have a poor appetite, have ongoing diarrhoea or have other signs that your Crohn's disease may be active, speak to your GP or IBD team. They can assess whether your disease is controlled and whether weight management treatment is appropriate.
This is particularly important if you are underweight, struggling to eat enough or have known nutritional deficiencies. Losing weight through treatment is not the right goal if you are already struggling to maintain adequate nutrition.
Getting the Order Right
There is no single rule that says everyone with Crohn's disease must see a gastroenterologist before considering Mounjaro. However, involving your IBD or gastroenterology team can be particularly helpful if your disease is active, you have had complications, or you have a history of strictures or bowel obstruction.
An online weight management consultation may not have access to your complete IBD history, including previous endoscopy results, imaging, blood tests or faecal calprotectin results. Sharing relevant information with your prescriber helps them make a more informed decision about whether Mounjaro is suitable for you.
This does not automatically rule out treatment. It simply means that your Crohn's disease should form part of the clinical assessment rather than being treated as a separate issue.
If you would like to discuss Mounjaro treatment alongside your Crohn's disease management, start your free consultation, and make sure your prescriber knows about your IBD history and current treatment.
Sources
- Mounjaro (tirzepatide) Summary of Product Characteristics, Electronic Medicines Compendium
- Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP 1 Receptor Agonists in Inflammatory Bowel Disease, Alimentary Pharmacology & Therapeutics, 2025, published online November 2025 and included in the 2026 issue
- Glucagon like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta analysis, 11 observational studies involving 16,242 people with IBD
- GLP 1 receptor agonist systematic review and meta analysis examining weight and metabolic outcomes in people with IBD
Medical Disclaimer
This page provides general information about Mounjaro and Crohn's disease. It is not a substitute for personalised medical advice, diagnosis or treatment.
Mounjaro is a prescription medicine and is not licensed to treat Crohn's disease. Whether it is appropriate for you depends on your individual health, Crohn's disease activity, medical history and other medicines. The UK prescribing information advises caution in people with severe gastrointestinal disease, including severe gastroparesis.
If you develop new or worsening digestive symptoms, repeated vomiting, severe or persistent abdominal pain, significant abdominal swelling, signs of dehydration or rectal bleeding, contact your GP, IBD team or another appropriate healthcare professional. Some of these symptoms can be caused by Crohn's disease or other conditions and should not automatically be attributed to Mounjaro.
Mounjaro can cause nausea, vomiting and diarrhoea, which may lead to dehydration and, in some cases, a decline in kidney function.
If you use an oral contraceptive and have obesity or are overweight, the current UK prescribing information advises using a non oral contraceptive method or adding a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. Speak to your prescriber or pharmacist if you need advice about contraception.
If you have questions about your specific treatment, speak to your prescriber, pharmacist, GP or IBD team.
